Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?

Future Oncol. 2018 Dec;14(29):2997-2999. doi: 10.2217/fon-2018-0604. Epub 2018 Nov 9.

Affiliations

¹ Division of Oncology, S Orsola-Malpighi Hospital, Bologna, Italy.
² Oncology Unit, SG Moscati Hospital of Taranto, Taranto, Italy.
³ Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
⁴ Section of Pathological Anatomy, School of Medicine, United Hospital, Polytechnic University of the Marche Region, Ancona, Italy.

PMID: 30411632
DOI: 10.2217/fon-2018-0604

No abstract available

Keywords: clinical trials; immunotherapy; metastatic renal cell carcinoma.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / immunology
Clinical Trials as Topic
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
Costimulatory and Inhibitory T-Cell Receptors / immunology
Humans
Immunotherapy / methods*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / immunology
Patient Selection
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Costimulatory and Inhibitory T-Cell Receptors